GSKGlaxoSmithKlineSigning up patients
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Neoplasms, Head and Neck
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 864 (planned)
- Started
- Mar 21, 2024
- Main results expected
- Jun 30, 2028
- Fully finished
- Oct 26, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Event-free Survival (EFS) Assessed by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06256588 · record last updated 2026-05-26 · checked 2026-11-09 15:47 UTC